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Abstract: Radiotherapy with or without surgery is a common choice for brain tumors in dogs. Although
numerous studies have evaluated use of three-dimensional conformal radiotherapy, reports of definitive-
intent, intensity modulated radiation therapy (IMRT) for canine intracranial tumors are lacking. IMRT
has the benefit of decreasing dose to nearby organs at risk and may aid in reducing toxicity. However,
increasing dose conformity with IMRT calls for accurate target delineation and daily patient positioning,
in order to decrease the risk of a geographic miss. To determine survival outcome and toxicity, we
performed a multi-institutional retrospective evaluation of dogs with brain tumors treated with IMRT.
Fifty-two dogs treated with fractionated, definitive-intent IMRT at four academic radiotherapy facilities
were included. All dogs presented with neurologic signs and were diagnosed via magnetic resonance
imaging. Presumed radiological diagnoses included 37 meningiomas, 12 gliomas, and 1 peripheral nerve
sheath tumor. One dog had two presumed meningiomas and one dog had either a glioma or meningioma.
All dogs were treated in the macroscopic disease setting and were prescribed a total dose of 45-50 Gy
(2.25-2.5 Gy per fraction in 18-20 daily fractions). Median survival time for all patients, including seven
cases treated with a second course of therapy was 18.1 months (95% CI 12.3-26.6 months). As previously
described for brain tumors, increasing severity of neurologic signs at diagnosis was associated with a
worse outcome. IMRT was well tolerated with few reported acute, acute delayed or late side effects.
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Abstract 24 
Radiotherapy with or without surgery is a common choice for brain tumors in dogs.  Although 25 
numerous studies have evaluated use of three-dimensional conformal radiotherapy, reports of 26 
definitive-intent, intensity modulated radiation therapy (IMRT) for canine intracranial tumors are 27 
lacking. IMRT has the benefit of decreasing dose to nearby organs at risk and may aid in 28 
reducing toxicity.  However, increasing dose conformity with IMRT calls for accurate target 29 
delineation and daily patient positioning, in order to decrease the risk of a geographic miss.  To 30 
determine survival outcome and toxicity, we performed a multi-institutional retrospective 31 
evaluation of dogs with brain tumors treated with IMRT.  Fifty-two dogs treated with 32 
fractionated, definitive-intent IMRT at four academic radiotherapy facilities were included.  All 33 
dogs presented with neurologic signs and were diagnosed via magnetic resonance imaging.  34 
Presumed radiological diagnoses included 37 meningiomas, 12 gliomas, and 1 peripheral nerve 35 
sheath tumor.  One dog had two presumed meningiomas and one dog had either a glioma or 36 
meningioma.  All dogs were treated in the macroscopic disease setting and were prescribed a 37 
total dose of 45-50 Gy (2.25-2.5 Gy per fraction in 18-20 daily fractions).  Median survival time 38 
for all patients, including seven cases treated with a second course of therapy was 18.1 months 39 
(95% CI 12.3-26.6 months).  As previously described for brain tumors, increasing severity of 40 
neurologic signs at diagnosis was associated with a worse outcome.  IMRT was well tolerated 41 
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Text, Original Investigations 47 
 48 
Introduction 49 
Conventional, fractionated radiation therapy (RT) with or without surgery is the treatment 50 
of choice for brain tumors in dogs1-2.  Two studies have evaluated the use offinely fractionated 51 
(≤ 3 Gy per fraction), three-dimensional, conformal radiotherapy (3DCRT) without surgery with 52 
median survival times of 19 – 23 months1-2.  The total prescribed dose in these studies ranged 53 
from 35 – 54 Gy.  Dose per fraction varied between 2.5 – 3 Gy per fraction. Acuteradiation side 54 
effects (ocular, oral, aural) wereseen in 45% of dogs in one study2 and were not mentioned in the 55 
other study1. Reported late side effects were absent in one study1 and found in 23% in another2; 56 
late side effects were only seen at a low frequency, characterized by grade 1 skin, CNS and 57 
ocular effects2.Late side effects may be underreported in these studies due to a lack of 58 
standardized follow-up. 59 
Intensity modulated radiation therapy (IMRT)can result in a greater degree ofdose 60 
conformityand a steeper dose gradient outside of the target when compared to 3DCRT3.  This 61 
feature can be used to selectively reduce dose of ionizing radiation to nearby organs at risk3. In 62 
consequence, side effectsmay decrease and the quality of life of the patient improves4-5.  63 
However, the increasing conformity of IMRT calls for accuratetarget delineation and 64 
confirmation of daily patient positioning. Errors in positioning and inaccuracies or 65 
misconceptions of the extent of tumor infiltration have the potential to increase the risk of a 66 
geographic miss compared to less conformal 3DCRT6-7.  Accurate target contouring is especially 67 
important, as canine meningiomas have been reported to be more invasive than their human 68 
counterparts8.Additional concerns arise with the use of IMRT.  Integral dose, or the volume 69 
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integral of the dose deposited in the patient, rises with certainIMRT techniques, especially with 70 
helical delivery systems such as Tomotherapy, and increased integral dose might be related to 71 
ahigher risk of secondary cancers9-11.  There is also increased cost and time needed for planning 72 
and delivery of IMRT compared to 3DCRT12. 73 
There has been an increase in use of IMRT for the treatment of canine brain tumors, but 74 
the true clinical benefit, if any, of IMRT over 3DCRT when conventionally-fractionated 75 
protocols are used is not known.  Although there are numerous publications investigating the use 76 
of 3DCRT and SRT for canine brain tumors, there is no data reporting outcome and toxicity of 77 
conventionally-fractionated IMRT.We hypothesized that dogs treated with conventionally-78 
fractionated, definitive intent IMRT for brain tumors would have a similar to improved outcome 79 
with comparable side effects compared to dogs treated with definitive-intent 3DCRT. 80 
Methods and Materials 81 
This was multi-institutional retrospective study.The medical records of dogs with primary 82 
brain tumors treated with definitive intent IMRT with image-guided radiation therapy (IGRT) at 83 
the veterinary teaching hospitals of the University of Wisconsin-Madison, University of Zurich, 84 
University of Guelph and The Ohio State University were retrospectively reviewed.  Inclusion 85 
criteria consisted of treatment with definitive-intent, conventionally-fractionated radiation 86 
therapy (18-20 fractions) for a primary, non-pituitary intracranial neoplasm diagnosed by 87 
magnetic resonance imaging (MRI).  An ACVR board certified radiation oncologist from each 88 
institution evaluated each dog for inclusion in the study.Dogs were included in the study on an 89 
intent-to-treat basis such that all dogs that began radiotherapy were included in the analysis 90 
regardless of whether they completed treatment.  Dogs with primary pituitary masses, previously 91 
surgically debulked/excised intracranial tumors, suspected round cell or metastatic tumors, and 92 
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dogs with inadequate follow-up (no recheck examinations or contact with the treating hospital 93 
after the end of radiation therapy) were excluded.  Data recording was based on each 94 
independent radiation oncologist. Pituitary masses were excluded as previous literature has 95 
demonstrated a disproportionate outcome compared to other intracranial tumors1. Participating 96 
radiation oncologists were provided data extraction forms that requested information about 97 
signalment, presenting neurologic signs, pre-treatment laboratory work, staging results (thoracic 98 
and abdominal imaging), pre-treatment medications, concurrent diseases, tumor type, method of 99 
diagnosis, tumor imaging, tumor localization (supratentorial, infratentorial), radiation delivery 100 
system and technique, radiation prescription, radiation dose statistics, patient positioning 101 
methodology, radiation side effects, follow up visits, any documented clinical or imaging 102 
response to radiation, additional radiation treatments, neurologic progression, cause of death and 103 
date of death or euthanasia.  Follow-up information was obtained from medical records as well 104 
as phone calls to the primary veterinarians and owners.  Grade of neurologic signs was assigned 105 
retrospectively by the primary author and defined according to a previously published protocol: 106 
grade 1 (i.e. seizures only or mild neurologic signs), grade 2 (moderate to marked neurologic 107 
signs) and grade 3 (stupor or non-ambulatory)13. 108 
The radiation treatment plan of each patient was reviewed by the participating radiation 109 
oncologist from the institution where the patient was treated.  Each institution had its own 110 
methods for optimization and setting of constraints (i.e. brain minus GTV or brain minus 111 
PTV).  For reporting purposes, brain volume was defined as the volume of the brain 112 
including the GTV.Dose statistics for target volumes (GTV, CTV, PTV) were recorded, 113 
including median dose (D50%), D2%, D98% and D95%3, 14.Organ at risk statistics were 114 
recorded for the brain, specifically D2% and Dmean3, 14.  Dose homogeneity and conformity 115 
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calculations were based on the RTOG conformity index, van’tReitconformityindex, and 116 
homogeneity index (Table 1)15. 117 
Clinical improvement of neurologic signs was reported based on available documentation 118 
in the medical records.Objective tumor response was assessed via imaging (MRI) and tumor 119 
response criteria were not standardized due to the retrospective nature of this study.  Centralized 120 
imaging review was not performed.  Tumor response was considered complete if the tumor was 121 
described as having disappeared on follow up imaging.  Tumors that persisted on follow up 122 
imaging but measured smaller in size compared to before treatmentwere classified as having a 123 
measurable response.  Progressive disease was reported if neurological signs worsened due to 124 
radiation side effects or tumor enlargement based on MRI.If the tumor responded but the dog 125 
exhibited progressive neurologic signs, this was defined as progressive disease.  Stable disease 126 
was reported if the tumor size did not change.  Acute side effects (occurring within 90 days of 127 
radiation therapy) and late side effects (occurring > 90 days after radiation therapy)were graded 128 
according to the Veterinary Radiation Therapy Oncology Group (VRTOG) radiation morbidity 129 
scoring scheme16.Acute delayed side effects were defined as having occurred between 1 – 3 130 
months after radiation therapy.Late side effects were reported if confirmed via necropsy, 131 
suspected on imaging or suspected by the participating radiation oncologist based on 132 
interpretation of the medical record. 133 
Statistics 134 
Variables are summarized by N (%), mean (SD), or median (IQR) when appropriate 135 
based on variable distribution.  Overall survival (OS) is defined by the date of initiation of 136 
radiotherapy to date of death from any cause. Dogs that were alive at the end of the study or lost 137 
to follow up were censored at the date of last available follow-up (hospital visit or phone call 138 
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with owner or primary veterinarian). Progression free survival (PFS) was defined by the date of 139 
initiation of radiotherapy to the date of documented clinical neurologic progression, progression 140 
on imaging or death from any cause, whichever came first.  Dogs that were alive and without 141 
evidence of progression were censored for PFS analysis at the date of the last evaluation. OS and 142 
PFS were analyzed using the Kaplan-Meier method, and median OS, PFS were computed with 143 
associated 95% confidence interval. Median follow up time was calculated for dogs censored.  144 
Cox Proportional Hazard model was used to assess the effect of the following prognostic factors: 145 
grade of neurologic signs (grade 1 vs. 2+3), tumor location (infratentorial vs. supratentorial), 146 
PTV to brain volume ratio and tumor type (meningioma, glioma) on OS. Grade 2+3 were 147 
grouped together to allow for more robust statistical evaluation as there was onlyone dog with 148 
grade 3 neurologic signs. All statistical tests were two-sided, and 5% (p<0.05) was set as the 149 
level of significance. Statistical analyses were performed by a biostatistician (YC) in R 3.4.2, 150 
including the “survival” and “survminer” packages. 151 
Results 152 
Patient Characteristics 153 
A total of 52dogs were included and were treated from2011 to 2018.  Twenty dogs were 154 
from the Ontario Veterinary College, 17 from the University of Wisconsin-Madison, 12 from the 155 
University of Zurich and 3 from The Ohio State University.Signalment, age, weight, diagnosis, 156 
location and grade are included in Table 2.  All brain tumors were presumptively diagnosed 157 
based on MRI.  Biopsies were not performed to confirm diagnosis before treatment in any case.  158 
A portion of the dogs (8) in this study population were included in a previous publication17. 159 
All dogs presented with neurologic signs. Presenting signs included seizures (30), cranial 160 
nerve deficits (25), gait abnormalities (21), change in behavior (17), inappetence (6), decreased 161 
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alertness /obtundation (6), and blindness (3).  A total of 32 dogs presented with grade 1 162 
neurologic signs (including 2/3 blind dogs), 18 with grade 2 (including 1/3 blind dogs) and 1 163 
with grade 3.  Grade was not available in one dog.  There was no statistically significant 164 
difference in cancer type by grade with Glioma rate in grade 1 (5/30 [16.7%]) vs grades 2&3 165 
(7/19 [36.8%]; p=0.173).  There was also no statistically significant difference in PTV:Brain 166 
ratio by cancer type with median (IQR) of the ratio in glioma subjects being 0.22 (0.14, 0.36) 167 
compared to 0.20 (0.10, 0.32) in meningioma subjects (p=0.351).All dogs except for two were 168 
prescribed prednisone at the time of diagnosis resulting in neurologic improvement in thirty-169 
seven dogs.  Prednisone use did not improve neurologic signs in 10 dogs, and change in 170 
neurologic signs were unknown in 5 dogs. 171 
Thoracic imaging (computed tomography (CT) or radiography) was performed in all but 172 
one dog, abdominal imaging (CT or ultrasound) was performed in 44 dogs, and pre-anesthetic 173 
bloodwork was performed in all dogs.  The technical parameters and equipment used for 174 
diagnostic imaging was not available. No significant co-morbidities were diagnosed at the time 175 
of radiotherapy in any case. 176 
Radiation Therapy 177 
Treatment planning CT scans were performed for each patient in the treatment position.  178 
Treatment position consisted of sternal recumbency using an immobilization system specific to 179 
each institution, including a customized bite block and vacuum mattress in all cases. The bite 180 
block systems were designed and validated at their respective institutions.CT Scans were 181 
performed using the following helical CT scanner:  GE Bright Speed 16-slice (GE Healthcare, 182 
Milwaukee, Wisconsin, USA), GE Light Speed 64-slice (GE Healthcare, Milwaukee, Wisconsin, 183 
USA), Philips 16 Brilliance 16-slice (Philips AG, Zurich, Switzerland) and GE Lightspeed 8-184 
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slice (GE Healthcare, Milwaukee, Wisconsin, USA).  MRI scans were performed using the 185 
following machines: Philips Inguinia 3T (Philips AG, Zurich, Switzerland), Philips Inguinia 3T 186 
(Philips, Cleveland, Ohio, USA), GE Sigma 1.5T (GE Healthcare Canada, Mississauga, ON, 187 
Canada) and GE Sigma 1.5T (GE Healthcare, Milwaukee, Wisconsin, USA).  In some patients, 188 
MR-studies from the referring neurologists were used / imported for contouring.  Contours 189 
weredrawn on 3-dimensional computed tomography, co-registered with MRI in 47 / 52 190 
cases.Thickness of CT slices varied between 0.6 – 2 mm, while both slice thickness and gap 191 
thickness on MRI varied between 0.6– 5.5 mm.  Gross tumor volume (GTV) was contoured as 192 
contrast enhancing tumor on CT, adapted accordingly if fused with MRI.Clinical target volume 193 
(CTV) varied between 0-5 mm in most dogs, whilesomeinstitutionsonlyincluded a CTV that 194 
encompassed edema if it was present on the T2/Flair MRI sequences (16 dogs).  Determination 195 
of the CTV margin was influenced by a number of factors, including imaging findings (Ill-196 
defined vs well-defined), tumor location and patient size, among others.  These factors 197 
varied between institutions.Planning target volume (PTV) varied between 1-3 mm.Forty-three 198 
dogs had a PTV of 2 mm, six dogs had a PTV of 3 mm and two dogs had a PTV of 1 mm.  The 199 
PTV expansion was not available in one dog but was suspected to be 2 mm.Inverse planningwith 200 
heterogeneity corrections was performed using the Eclipse Treatment Planning system (Varian 201 
Medical Systems, Palo Alto, CA; Versions 10.0, 11.5, 13 and 13.06; AAA algorithm) at all sites 202 
except the University of Wisconsin-Madison where IMRT was planned using the Tomotherapy 203 
Planning Station Hi-Art system (Accuray Inc., Sunnyvale, CA, USA; Versions 3 to 5; 204 
convolution superposition algorithm). 205 
The treatment planning goal at all institutions was to deliver at least 95% of the 206 
prescribed dose to 95% of the PTV while minimizing dose to normal tissues, with some 207 
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institutions aiming for greater target coverage.  Optimization was performed in all institutions 208 
using dose volume cost functions.  One institution employed equivalent uniform dose (EUD) and 209 
a second employed an in-house normal tissue complication probability (NTCP)calculator18.  All 210 
plans were evaluated and approved by an American College of Veterinary Radiology (ACVR) 211 
certified radiation oncologist.Quality analysis was performed for all plans and consisted of film 212 
and a point measurement via ion chamber at one institution, film at another institution, ionization 213 
chamber array at the third institution and electronic portal imaging device (EPID) dosimetry 214 
verification at the fourth institution. 215 
All facilities used 6 MV photons beams.  Three facilities delivered radiation with 4-9 216 
isocentric, static, coplanar gantry angles using either static (step and shoot, n=1) or dynamic (n = 217 
2) IMRT.  These facilities used conventional C-arm linear accelerators including Siemens 218 
OncorTM Digital Linear Accelerator (Siemens Medical Laboratories, Walnut Creek, CA), Varian 219 
Clinac 2300 iX and ClinaciX (Varian Medical Systems, Palo Alto, CA).  The fourth facility 220 
delivered radiation using a helical tomotherapy unit (Accuray Inc., Sunnyvale, CA, USA) unit. 221 
All patients had daily on-board imaging performed before treatment delivery (megavoltage 222 
computed tomography (MVCT, 17 dogs), kilo voltage (kV) cone beam CT (kVCBCT, 23 dogs), 223 
orthogonal kV images (9 dogs) or a combination of kVCBCT or orthogonal kV images (3 dogs).  224 
Dogs were prescribed a total dose of 45 – 50 Gy delivered in daily fractions on a Monday to 225 
Friday schedule [2.5 Gy x 20 (n = 38), 2.4 Gy x 20 (n = 3), 2.25 Gy x 20 (n =2), 2.5 Gy x 18 (n = 226 
9)].  Radiation dose statistics are listed in Table 3.Dose conformity and homogeneity indices are 227 
shown in Table 4. 228 
Two patients had deviations to the intended radiation protocol.  One patient experienced a 229 
one-week treatment delay due to mechanical failure of the treatment machineafter receiving 5 230 
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fractions of 2.5 Gy.  This patient received an additional 14 fractions of 3.2 Gy.  Another patient 231 
missed the first fraction of radiation, so this patient was given 19 fractions of 2.63 Gy.Four dogs 232 
(8%) died during radiotherapy.  One dog died while being anesthetized prior to the tenth 233 
radiation fraction.  Another dog died six days after starting radiation, with the cause of death 234 
suspected to be due to marked aspiration pneumonia.The third dog was euthanized three days 235 
after treatment start due to dull mentation and progressive clinical signs during treatment that 236 
were not responsive to supportive medications.  The fourth dog was euthanized three days after 237 
starting radiation therapy due to worsening neurologic status in the face of treatment. 238 
Clinical Response to Treatment 239 
Thirty-nine dogs (75%) improved neurologically during or shortly after radiation   240 
therapy.  Many of these patients received prednisone, potentially confounding the effect of 241 
radiation on neurologic improvement.  Four dogs displayed stable neurologic signs during and 242 
after treatment for an overall clinical benefit of 83% (43 / 52).  Information about the duration of 243 
prednisone use, such as duration of use or dosage, was not obtained. 244 
 Seventeen dogs had recheck MRI or CT’s performed after radiotherapy.The reason for 245 
re-imaging was not obtained and likely varied between evaluations of tumor size as a regular 246 
recheck versus progressive neurologic signs.  Ten of the re-imaged dogs had measurable 247 
responses, one being a complete response (range of 3 to 16 months). Two dogs diagnosed 248 
with gliomas had presumedintraventricular metastasis at 3 and 6 months post radiation. One 249 
patient had a measurable response on imaging 26 months after treatment but was clinically 250 
progressive with worsening neurologic signs.Four dogs had ameasurable response at 4 to 15 251 
months and went on to develop progressive disease 3 to 7 months later. 252 
Follow up and Survival 253 
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Eight dogs were still alive at the time of analysis and three were lost to follow up.  254 
Median time to follow up in the surviving animals was 24 months (IQR of 18.7, 26.1).Twenty-255 
five(27 / 52) dogs died due to worsening neurologic status.All four dogs who died during 256 
radiation treatment were presumed to have died due to neurologic disease and are included in 257 
this number. Information regarding neurologic progression and cause of death was not available 258 
in sevendogsso progression free survival was able to be determined in 45 dogs.Fivedogs died 259 
without neurologic progression due to other causes (osteosarcoma, zinc toxicity, histiocytic 260 
sarcoma, aspiration pneumonia 1 month after completion of radiation therapy,and severe hind 261 
limb arthritis) whereas one died after neurologic progression due to a large liver mass.  One dog 262 
presented for cough and subcutaneous mass on the lateral thorax as well as pulmonary 263 
metastatic disease 9 months after being treated for a presumed meningioma.No sampling of 264 
the subcutaneous mass or pulmonary metastatic disease was performed.  This dog had yet to 265 
neurologically progress after treatment.  Of the 8 animals still alive at the time of analysis, three 266 
had progressive disease and 5 were alive without evidence of progression.  Progression of 267 
neurologic signs was correlated with progression on imaging (MRI) in six cases. 268 
Median OS for all patients was 18.1 months (95% CI: 12.3 - 25.3 months).  Median PFS 269 
was 12.7 months (95% CI: 7.8 to 17.7 months).  Higher grade of neurologic signs (grade 2+3 vs 270 
grade 1) (P = 0.021) was significantly associated with a worse outcome (Table 5). 271 
Eight dogs received additional treatments after developing progressive neurologic signs 272 
and / or imaging findings suspicious for tumor progression.  Seven dogs were retreated with 273 
radiation.  Radiation protocols consisted of the following:  3 fractions of 5 Gy (2 dogs; Monday 274 
Wednesday, Friday), 3 fractions of 8 Gy (Monday, Wednesday, Friday), 14 fractions of 2.2 Gy 275 
(consecutive), 10 fractions of 3 Gy (2 dogs, consecutive) and 5 fractions of 4 Gy (consecutive).   276 
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One dog was treated with oral chemotherapy (CCNU).  Clinical response was available for one 277 
dog whose neurologic signs completely resolved and who lived for another 27 months (14 fx x 278 
2.2 Gy).  Response to therapy was not available for the other dogs that received additional 279 
treatments. 280 
Adverse Effects 281 
Information regarding acute side effects was retrospectively evaluated in all cases.  If 282 
there was no mention of side effects in the medical record, the patient was presumed to have had 283 
no side effects. Overall, acute side effects were reportedin 3 / 54 dogs (5.5%) and, when 284 
reported, were self-limiting.Reported acute side effects consisted of one possible grade I aural 285 
complication characterized bya waxy external horizontal ear canal occurring two weeks after 286 
radiation, one possible acute delayed grade 1 neurologic sign characterized by mild ataxia 287 
occurring 47 days after the end of radiation therapy that resolved with corticosteroid 288 
administration, and one possible acute grade 1 episode consisting of loss of balance, confusion 289 
and delayed proprioception. 290 
 Late side effects were also minimal, with no clear late side effects reported.  The 291 
possibility of late brain effects cannot be ruled out in the group of twenty-nine dogs that had 292 
neurologic progression.  Post mortem examinations were performed on 7 dogs, six of which had 293 
available records.  Of the six dogs with histopathologic information, the imaging diagnosis was 294 
confirmed in five dogs while one had an undifferentiated tumor that was originally diagnosed by 295 
MRI as either a glioma or meningioma.  None of the gross or histopathologic descriptions were 296 
indicative of late radiation side effects. 297 
Discussion 298 
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This study’s aim was to evaluate the survival outcome and side effect profile of fractionated, 299 
definitive-intent IMRTin dogs with brain tumors from four veterinary institutions.  Themedian 300 
survival of 18.1 months (543 days) is in line with previously published studies that used 301 
definitive intent 3DCRT1-2, 19.Rohrer Bley et al.reported a median survival time for dogs treated 302 
with conventionally fractionated 3DCRT of 23.3 months (95% CI, 19.6 – 27 months), or 39.1 303 
months (95% CI, 23.1 - 55.2 months) when death was attributed to tumor-related causes1.  In a 304 
study byKeyerleber et al., the median survival timewas19.2 months (IQR = 9.1 – 27.6months) 305 
while a study by Treggiariet al.found a median survival time 25.2 months (95% CI 7 – 43.4 306 
months) in dogs with infratentorial brain tumors2, 19.  However,it is difficult to compare 307 
retrospective studies, due to variable delivery techniques, fractionation protocols, followup and 308 
diagnostics.  309 
In physician-based medicine, there is ongoing discussion as to the efficacy of IMRT for 310 
tumor controlsince the technique itself does not enhance prescribed dose and therefore may not 311 
improvetumor control probability4, 20.Rather, due to the steeper dose gradients and potentially 312 
smaller margins, the risk for geographic miss theoretically could be more likely. In studies of 313 
head and neck tumors in people, when an increase in locoregional control is found with IMRT, it 314 
is confounded by the concurrentuse of intense chemotherapeutic regimens20.  There is minimal 315 
literature concerning the effect of IMRT on locoregional control of intracranial tumors in people.  316 
In one study, there was no survival advantage with IMRT compared to 3DCRT in a population 317 
of glioblastoma patients4. 318 
Acute side effects in our study were minimal.  Some acute side effects that were reported 319 
were questionably associated with radiation therapy (one dog displayed waxy horizontal ears 320 
canals), however reduced side effects may be an important ethical consideration in veterinary 321 
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patients and a potential benefit of IMRT in veterinary patients.Reported late side effects were 322 
minimal as well, however these may have been underreported due to the lack of imaging or 323 
necropsy in dogs with progressive neurologic signs.In people with intracranial tumors, the effect 324 
of IMRT on side effects is not clear. One publication suggested that IMRT decreased the 325 
incidence of grade 1 and 2 neurological toxicities compared to 3DCRT4.  The decrease in side 326 
effects brought about by IMRT is more appreciable and reproducible in the cases of xerostomia 327 
and dental disease in head and neck patients21-22.  The disparity between the impact of IMRT in 328 
head and neck patients vs. brain tumor patients with respect to reducing side effects could be 329 
explained by the high tolerability of normal brain tissue to conventionally-fractionated radiation 330 
prescription resulting in minimal toxicity even when less conformal techniques are used. 331 
Dogs with more severe neurologic signs (grade 2, 3) had a significantly worse outcome than 332 
dogs with grade 1 neurologic signs. Neurologic status has previously been found to be a 333 
significant prognostic factor17. As with most veterinary studies grade was assigned 334 
retrospectively based on record review which may lead to inaccuracies. Although it has been 335 
previously suggested that gliomas have a more aggressive biologic behavior and inferior 336 
outcome compared to other tumor types17, tumor type based on imaging diagnosis was not 337 
associated with outcome in the present study. 338 
There was a wide variation in the dose conformity delivered at the four institutions involved 339 
in this study (Table 4).  Generally, RTOG conformity index of 1 indicates that the target volume 340 
and the volume of tissue receiving the prescription radiation dose are the same (irrespective of 341 
overlap) and a van’tReitvalue of > 0.8 indicates good conformity of the prescription 342 
isodosevolumeto the target volume.  The importance of high dose conformitywhen 343 
usingconventionally-fractionated radiotherapy protocols for brain tumor irradiated is not defined.  344 
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As mentioned above, conformity may be less important than in other areas of the body due to the 345 
high tolerance of normal brain tissue to low-doses of radiation per fraction.  Conventionally-346 
fractionated radiation treatments using less-conformal 3DCRT have been shown to be safe in 347 
dogs with brain tumors, with minimal acute or late side effects documented in the literature1-2.  348 
Achieving a high conformity index, therefore, may not have been a treatment planning priority at 349 
all institutions in this study.  Conformity index can also be affected by treatment planning 350 
strategies that prioritize sparing of normal brain over less critical adjacenttissues;  for example, 351 
some treatment planners may accept dose spill off into adjacent bone and muscle in order to 352 
obtain high conformity with sharp dose fall off in surrounding normal brain (such as brain 353 
stem).Therefore, the wide variation in conformity indices between institutions reported in this 354 
study may be the result of a number of factors, including different optimization goals, different 355 
treatment planning strategies, as well as different radiation delivery systems.  Determining what 356 
role, if any, IMRT has in tumor control and probability of side effects in brain tumor irradiation 357 
compared to3DCRT (forward-planning) techniques when conventionally-fractionated protocols 358 
are used requires further investigation. 359 
The homogeneity index varied between institutions suggesting that some institutions 360 
accepted greater maximal radiation doses within the tumor. While this could theoretically impact 361 
outcome, the degree of dose heterogeneity was less than 15% above the prescribed dose in 362 
almost all cases, which is considered within the range of uniform dosing.  When aiming for very 363 
conformal dose delivery and sharp fall off, IMRT optimization can require dose heterogeneity 364 
withinthe tumor.  Thus, while it was common to aim for a uniform dose distribution with 3DCRT 365 
in the past, this is nowadays sometimes questioned as it limits the freedom of the optimizer to 366 
achieve highly conformal dose distributions with IMRT23. 367 
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The total dose delivered in this study (45 – 50 Gy) may not be high enough to provide 368 
adequate tumor control, however if an 
!
"
 for normal brain tissue of 2 or 3 is assumed, 50 Gy in 20 369 
fractions is an EQD2 of 55 - 56.25 Gy which approaches the tolerance doses for the brainstem 370 
and optic pathway of 55-60 Gy reported in QUANTEC28.This prescription varied across the 371 
facilities and was dependent on clinician experience and comfort level.IMRT’s greater 372 
conformity enables dose escalation within the target, such as with hypofractionated or 373 
stereotactic radiotherapy (SRT)24.  Stereotactic radiation therapy has been increasingly utilized in 374 
veterinary medicine for the treatment of intracranial tumors25-27.  Reported survival times have 375 
range between 13.3 – 18.7 months25-27, with one publication noting an increase in acute delayed 376 
radiation side effects26.  To combat the risk of side effects, recent literature has been published 377 
evaluating more moderately hypofractionated protocols for brain tumors17-18. 378 
There was a limited opportunity to assess tumor response in this study, as follow up imaging 379 
was not routinely performed and was performed at various time points along disease 380 
progression.Owners elected to reimage either during routine rechecks or upon progression of 381 
neurologic signs.  In cases where a response was seen, response criteria were not standardized. 382 
This is an unfortunate but accepted reality of retrospective studies in veterinary oncology.  383 
Objectively assessing tumor response was not the primary goal of this study. 384 
Limitations of this multi-institutional retrospective study include small sample size, non-385 
standardized follow up, and lack of histopathologic diagnosis of brain tumors.  Contouring 386 
techniques were not standardized; CTV and PTV were defined differently among institutions and 387 
even among individuals at the same institution, which could skew the prognostic value of factors 388 
such as PTV/brain ratio.  In addition, brain was assessed as an OAR to include GTV.Treatment 389 
planning goals were not standardized and different radiation delivery systems were used, 390 
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impacting the degree the dose conformity and homogeneity. The date of progression was 391 
requested in the data extraction forms however this information was not available in a large 392 
proportion of dogs.  Additionally, assessment of tumor progression is not always clear when 393 
retrospectively reviewing data.  Consequently, the estimated progression free survival may not 394 
represent the true time to progression in this population of dogs.  Lack of standardized follow-up 395 
is a major limitation when evaluating radiation toxicity.   396 
The median survival time of dogs with brain tumors treated with definitive-intent IMRT at 397 
four veterinary institutions is in line with previous reports of less-conformal 3DCRT.  The high 398 
degree of dose conformityachievable with IMRT enables dose escalation and the opportunity to 399 
perform hypofractionated treatments17. A prospective clinical study with standardized techniques 400 
and follow-up is required to confirm any benefits or limitations of IMRT compared to 3DCRT. 401 
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Table 1.  Various indices used for plan evaluation. 532 
















TVRI = Target volume (PTV) covered by the reference isodose.  TV = Target volume 533 



















Table 2. Descriptive summary statistics reported as N (%), mean (SD).  551 
Variable N = 52 
Age at diagnosis (yrs) 9.4 (2.4) 
Sex – female (23 spayed, 2 intact) 25 (48.1%) 
Sex – male (23 neutered, 4 intact) 27 (51.9%) 
Weight (kg) 24.3 (12.7) 
Presumed tumor type  
Glioma 12 (23.1%) 
Meningioma 38 (73.1%) 
PNST (Large brainstem component) 1 (1.9%) 
Glioma or meningioma 1 (1.9%) 
Location  
Infratentorial 18 (34.6%) 
Supratentorial 32 (61.5%) 
Both Intratentorial and Supratentorial 2 (3.8%) 
Neurological Grade  
1 32 (62.7%) 
2 and 3 19 (37.3%) 
 552 
PNST: peripheral nerve sheath tumor.  Two dogs had concurrent incidental pituitary tumors that 553 





















Target Volume (cm3) Brain Volume (cm3) and Dosimetry (Gy) Data 
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Target Dosimetry (Gy) Data  
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Homogeneity Delivery Type 
All 0.85 (0.37) 0.70 (0.19) 1.06 (0.03)  
University of Guelph 0.71 (0.16) 0.66 (0.19) 1.07 (0.02) Dynamic MLC 
The Ohio State 1.00 (0.15) 0.83 (0.12) 1.08 (0.01) Static MLC 
University of Wisconsin 1.05 (0.08) 0.79 (0.05) 1.04 (0.01) Tomotherapy 
University of Zurich 0.69 (0.27) 0.56 (0.20) 1.05 (0.04) Dynamic MLC 




Table 5.  Cox proportional hazard model hazard ratio on variables.  Hazard ratio reported 594 
as change per 0.1 units. 595 
Cox model covariates Variables   Hazard Ratio 
(95% CI) 
P values 
Institution Institution Guelph (reference)     
    OSU 0.49 [0.06, 3.74] 0.491 
    UW 1.35 [0.64, 2.87] 0.435 
    Zurich 0.91 [0.41, 2.03] 0.815 
Institution + Grade Grade Grade 1 (reference)     
    Grade (2&3) 2.45 [1.20, 4.97] 0.0135 
Institution + Tumor Tumor Giloma (reference)     
    Meningioma 
  
0.63 [0.28, 1.41] 0.263 
Institution + Location Location Infratentorial 
(reference) 
    






























  1.04 [0.24, 4.57] 0.955 
     
Institution + 
Coregistration 
Coregistration Yes 1.37 [0.42, 4.5] 0.60 
    No (Reference)     
          
     
Figure 1. Overall Survival.Median OS for all patients was 18.1 months (95% CI: 12.3 - 25.3 596 
months).   597 
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Figure 2.  Progression Free Survival.  Median PFS was 12.7 months (95% CI: 7.8 to 17.7 603 
months). 604 
 605 
